In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker

References

• Andersson T. (1996). Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 31:9–28
   PubMed Web of Science ®Google Scholar
• Arikawa Y, Nishida H, Kurasawa O, et al (2012). Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem 55:4446–56
   PubMed Web of Science ®Google Scholar
• Chong E, Ensom MHH. (2003). Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 23:460–71
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Watanabe F, et al (2002). Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453–60
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Sugimoto M, et al (2005). Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20:153–67
   PubMedGoogle Scholar
• Furuta T, Sugimoto M, Shirai N, Ishizaki T. (2007a). CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics 8:1199–210
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Kodaira M, et al (2007b). Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 81:521–8
   PubMed Web of Science ®Google Scholar
• Gamage N, Barnett A, Hempel N, et al (2006). Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 90:5–22
   PubMed Web of Science ®Google Scholar
• Graham DY, Shiotani A. (2008). Newer concepts regarding resistance in the treatment Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 5:321–31
   PubMedGoogle Scholar
• Hori Y, Imanishi A, Matsukawa J, et al (2010). 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 335:231–8
   PubMed Web of Science ®Google Scholar
• Hori Y, Matsukawa J, Takeuchi T, et al (2011). A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 337:797–804
   PubMed Web of Science ®Google Scholar
• Jenkins H, Sakurai Y, Nishimura A, et al (2015). Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 41:636–48
   PubMed Web of Science ®Google Scholar
• Kagami T, Sahara S, Ichikawa H, et al (2016). Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 43:1048–59
   PubMed Web of Science ®Google Scholar
• Katz PO, Scheiman JM, Barkun AN. (2006). Review article: acid-related disease – what are the unmet clinical needs? Aliment Pharmacol Ther 23(Suppl 2):9–22
   PubMed Web of Science ®Google Scholar
• Kogame A, Takeuchi T, Nonaka M, et al (2016). Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs. Xenobiotica. [Epub ahead of print]. doi: 10.1080/00498254.2016.1182667
   PubMed Web of Science ®Google Scholar
• Matsukawa J, Hori Y, Nishida H, et al (2011). A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol 81:1145–51
   PubMed Web of Science ®Google Scholar
• Mejia A, Kraft WK. (2009). Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol 2:295–314
   PubMedGoogle Scholar
• Murakami K, Sakurai Y, Shiino M, et al (2016). Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. [Epub ahead of print]. doi: 10.1136/gutjnl-2015-311304
   Web of Science ®Google Scholar
• Nishida H, Hasuoka A, Arikawa Y, et al (2012). Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers. Bioorg Med Chem 20:3925–38
   PubMed Web of Science ®Google Scholar
• Riches Z, Stanley EL, Bloomer JC, Coughtrie MWH. (2009). Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT “pie”. Drug Metab Dispos 37:2255–61
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Vagin O, et al (2007). The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol 41(Suppl 2):S226–42
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Nishimura A, Kennedy G, et al (2015). Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 6:e94
   PubMed Web of Science ®Google Scholar
• Senggunprai L, Yoshinari K, Yamazoe Y. (2009). Selective role of sulfotransferase 2A1 (SULT2A1) in the N-sulfoconjugation of quinolone drugs in humans. Drug Metab Dispos 37:1711–17
   PubMed Web of Science ®Google Scholar
• Shin JM, Inatomi N, Munson K, et al (2011). Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther 339:412–20
   PubMed Web of Science ®Google Scholar
• Yamada S, Onda M, Kato S, et al (2001). Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol 36:669–72
   PubMed Web of Science ®Google Scholar
• Yoneyama T, Teshima K, Jinnno F, et al (2016). A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography–tandem mass spectrometry. J Chromatogr B 1015:42–9
   PubMed Web of Science ®Google Scholar